预约演示
更新于：2026-10-28
Cassiopea SpA
更新于：2026-10-28
概览
标签
皮肤和肌肉骨骼疾病
小分子化药
关联
1
项与 Cassiopea SpA 相关的药物靶点 |
作用机制 AR拮抗剂 |
在研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2020-08-26 |
8
项与 Cassiopea SpA 相关的临床试验CTIS2023-507241-28-00
A phase 1, single-center, randomized, vehicle-controlled, openlabel clinical trial to evaluate the vasoconstriction properties of topical clascoterone (cortexolone 17α-propionate) cream 1% and clascoterone solution 5% in a vasoconstrictor assay compared to three other corticosteroids in subjects with healthy skin
开始日期2024-02-26 |
申办/合作机构 |
NCT05914805
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
Within this study, the Clascoterone solution will be compared to a placebo.
The study has 2 parts:
Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months.
Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data.
Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving.
Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo.
Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months.
Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects).
For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls.
Subjects taking part in this study will have the medical tests or procedures described below.
* They will be asked about their previous medical history and current medications.
* A brief physical examination will be performed.
* Vital signs, weight and height will be measured.
* Electrocardiograms will be performed.
* Subject's scalp will be checked for any signs of irritation.
* Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness).
* Blood draws and urine sample collection for safety laboratory tests.
* Subject will be asked to complete, on site, the following two questionnaires:
* Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use.
* Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment.
Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening.
Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.
Within this study, the Clascoterone solution will be compared to a placebo.
The study has 2 parts:
Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months.
Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data.
Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving.
Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo.
Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months.
Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects).
For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls.
Subjects taking part in this study will have the medical tests or procedures described below.
* They will be asked about their previous medical history and current medications.
* A brief physical examination will be performed.
* Vital signs, weight and height will be measured.
* Electrocardiograms will be performed.
* Subject's scalp will be checked for any signs of irritation.
* Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness).
* Blood draws and urine sample collection for safety laboratory tests.
* Subject will be asked to complete, on site, the following two questionnaires:
* Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use.
* Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment.
Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening.
Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.
开始日期2023-08-17 |
申办/合作机构 Cassiopea SpA [+3] |
NCT05910450
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
Within this study, the Clascoterone solution will be compared to a placebo.
The study has 2 parts:
Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months.
Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data.
Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving.
Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo.
Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months.
Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects).
For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls.
Subjects taking part in this study will have the medical tests or procedures described below.
* They will be asked about their previous medical history and current medications.
* A brief physical examination will be performed.
* Vital signs, weight and height will be measured.
* Electrocardiograms will be performed.
* Subject's scalp will be checked for any signs of irritation.
* Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness).
* Blood draws and urine sample collection for safety laboratory tests.
* Subject will be asked to complete, on site, the following two questionnaires:
* Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use.
* Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment.
Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening.
Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.
Within this study, the Clascoterone solution will be compared to a placebo.
The study has 2 parts:
Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months.
Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data.
Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving.
Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo.
Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months.
Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects).
For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls.
Subjects taking part in this study will have the medical tests or procedures described below.
* They will be asked about their previous medical history and current medications.
* A brief physical examination will be performed.
* Vital signs, weight and height will be measured.
* Electrocardiograms will be performed.
* Subject's scalp will be checked for any signs of irritation.
* Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness).
* Blood draws and urine sample collection for safety laboratory tests.
* Subject will be asked to complete, on site, the following two questionnaires:
* Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use.
* Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment.
Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening.
Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.
开始日期2023-06-21 |
申办/合作机构 Cassiopea SpA [+3] |
100 项与 Cassiopea SpA 相关的临床结果
登录后查看更多信息
0 项与 Cassiopea SpA 相关的专利（医药）
登录后查看更多信息
21
项与 Cassiopea SpA 相关的新闻（医药）2026-05-09
概述
脂溢性脱发（Androgenetic Alopecia，AGA），又称雄激素性脱发，是全球最常见的非瘢痕性脱发疾病，影响全球约12至20亿男性及相当比例的女性。其核心病理机制为：具有遗传易感性的毛囊在双氢睾酮（DHT）的持续作用下，逐渐发生微型化，导致毛发进行性稀疏和脱落。尽管该病的心理负担显著，但数十年来治疗格局几乎未曾发生根本性改变——直至近年，一批令人振奋的新疗法逐步进入临床视野，从再生医学到靶向分子治疗，为患者带来了新的希望。一、发病机制与流行病学
AGA的发生涉及遗传、内分泌和微环境多重因素的交汇。DHT通过与毛乳头细胞的雄激素受体（AR）结合，缩短生长期（anagen）、延长休止期（telogen），导致毛囊微型化和毛发逐步脱失。遗传易感性主要与AR基因及5α-还原酶基因的多态性相关。
流行病学数据显示，男性AGA的患病率随年龄增长显著上升，50岁以上男性中患病率可超过50%。女性AGA则多表现为弥漫性头顶稀疏，常与绝经后雌激素水平下降相关。该病对患者自尊、生活质量和心理健康的影响已有充分文献记录，在年轻起病者中尤为突出。二、现有标准疗法
目前，美国食品药品监督管理局（FDA）批准用于AGA的药物仅有两种：外用米诺地尔（Minoxidil） 和 口服非那雄胺（Finasteride），两者均已有数十年的临床应用历史。米诺地尔：通过促进血管扩张和延长生长期发挥作用，对男女均有效，但需长期使用，停药后疗效消退；非那雄胺：通过抑制5α-还原酶II型，降低头皮DHT浓度，主要用于男性，女性尤其是育龄期女性存在使用限制；度他雄胺（Dutasteride）：部分国家已批准，可同时抑制5α-还原酶I型和II型，效力更强，但全身性副作用风险相应增加。
上述疗法均存在一定局限：疗效因人而异、需终身维持、或因全身性激素暴露而带来安全顾虑（如非那雄胺相关的性功能障碍及情绪改变）。三、近年重要进展3.1 口服低剂量米诺地尔（Low-dose Oral Minoxidil，LDOM）
口服米诺地尔作为超说明书用法，近年来在临床实践中迅速普及，并积累了大量循证证据。多项系统综述和荟萃分析表明，低剂量（男性2.5–5 mg/日，女性0.25–1 mg/日）口服米诺地尔在改善毛发密度和患者主观满意度方面具有显著疗效。一项2025年发表于《美国皮肤病学会杂志》的荟萃分析确认，低剂量口服米诺地尔对血压的影响无统计学意义，安全性相对可接受，其主要副作用为多毛症（非头皮部位毛发增多），高血压患者需进行血压监测。该疗法为不能耐受外用制剂者提供了重要替代选项。3.2 Clascoterone 5%外用溶液——30年来首个全新作用机制
2025年12月，Cosmo制药（原Cassiopea）公布了Clascoterone（克拉斯可酮）5%外用溶液用于男性AGA的两项关键性III期临床试验（SCALP 1和SCALP 2）的顶线结果，在AGA治疗史上具有里程碑意义。
Clascoterone是一种局部雄激素受体拮抗剂，可直接在头皮毛囊水平阻断DHT与AR的结合，从而干预AGA的根本致病机制，同时避免全身性激素暴露。两项试验共纳入1,465例轻至中度男性AGA患者，在美国和欧洲51个中心开展，主要终点为靶区毛发数量（Target Area Hair Count，TAHC）变化。
结果显示：SCALP 1中，clascoterone 5%较安慰剂实现TAHC相对改善高达539%；SCALP 2中改善达168%。两项研究均达到统计学显著性（p<0.05），安全性良好，治疗相关不良事件发生率与赋形剂组相当，无显著全身性副作用。
监管申报工作已于2025年底在美国和欧洲同步推进，如获批准，Clascoterone将成为AGA领域30余年来首个全新机制的外用药物。3.3 富血小板血浆（PRP）及新型配方
PRP疗法是目前研究最为充分的再生医学手段之一。2020–2025年间发表的系统综述表明，PRP注射可通过释放多种生长因子（PDGF、TGF-β、VEGF等）激活毛乳头细胞、促进血管生成，在临床上改善毛发密度和直径。新型配方如富白细胞PRP（L-PRP）和可注射富血小板纤维蛋白（i-PRF）已见于初步研究，显示出与标准PRP相当或更优的疗效，但高质量随机对照试验仍有待开展。PRP与米诺地尔联合应用的方案已被多项研究证明优于单一疗法。3.4 外泌体（Exosome）疗法——新兴前沿
外泌体是细胞旁分泌通讯的重要载体，富含生长因子、miRNA和细胞因子，近年来作为AGA再生治疗的新方向备受关注。多项早期临床研究表明，源自间充质干细胞（MSC）或脂肪来源干细胞（ADSC）的外泌体可显著提高毛发密度和直径，且安全性良好。
2025年发表于Cureus的系统综述对外泌体疗法、PRP和米诺地尔进行了头对头比较，结论显示外泌体疗法在毛发再生和安全性方面展现出最为优异的结果，PRP次之，米诺地尔的可及性最佳但疗效相对有限。另有研究表明，微针联合外泌体外用可在12个月内实现约30–35根/cm²的毛发密度增加。
然而，外泌体疗法目前仍面临标准化不足、监管框架尚不明确以及高质量长期随访数据缺乏等挑战，尚不能作为一线推荐疗法。3.5 干细胞疗法
细胞治疗策略包括自体脂肪来源干细胞（ADSC）注射和毛囊来源细胞治疗，在临床前及早期临床研究中显示出挽救微型化毛囊的潜力。干细胞条件培养基（conditioned media）和间质血管组分（SVF）制剂也已被评估用于AGA。主要挑战包括疗效持久性不确定和制备流程标准化困难。3.6 微针疗法（Microneedling）
微针通过物理性微损伤激活创伤愈合通路，上调Wnt/β-catenin信号，促进毛囊生长。2025年发表的荟萃分析确认，微针联合米诺地尔的疗效显著优于单独使用米诺地尔，但各研究方案差异较大，单独使用微针超过一年的持久性数据尚不充分。3.7 siRNA与基因靶向疗法
以小干扰RNA（siRNA）为代表的靶向AR表达的新型疗法目前正在早期临床试验阶段，代表了AGA治疗的未来方向之一。此外，针对Wnt/β-catenin通路和前列腺素信号的分子靶向药物也处于研究开发阶段。生物制剂和靶向治疗时代的到来，为AGA治疗带来了更广阔的可能性。3.8 低能量激光疗法（LLLT）
获FDA认证的低能量激光/光生物调节装置作为辅助疗法已有一定证据支持，可与药物疗法联合使用，改善毛发生长，耐受性良好。四、治疗展望与临床意义
当前AGA治疗领域正处于历史性转型期：
Clascoterone 5%有望在2026年完成12个月安全性随访后正式提交监管批准，若成功将彻底打破AGA治疗近30年无新机制药物的局面；外泌体和干细胞疗法
代表再生医学的前沿方向，但仍需更大规模、设计更严格的随机对照试验确证其长期疗效；口服低剂量米诺地尔
已凭借充分的真实世界证据和系统综述数据，逐步进入多国临床指南的推荐范畴；联合治疗策略
（如雄激素靶向药物+再生疗法+设备辅助）正在成为难治性或进展性AGA管理的主流方向。
从遗传基因组学角度而言，多基因风险评分有望在未来实现AGA的精准化预测和个体化治疗选择，但尚处于研究阶段。结论
脂溢性脱发的治疗正经历近几十年来最为深刻的变革。在现有的米诺地尔和5α-还原酶抑制剂基础上，以Clascoterone为代表的靶向雄激素受体外用药物、以外泌体和干细胞为代表的再生医学手段，以及口服低剂量米诺地尔的广泛应用，共同构成了AGA新治疗时代的核心轮廓。未来几年，随着关键临床试验结果的陆续公布和监管审批的推进，临床医生将拥有更丰富的治疗工具箱，患者也将迎来更有效、更安全、更个体化的治疗选择。参考文献
Darwish R, et al. From Cells to Strands: A Systematic Review Comparing Exosome Therapy, Platelet-Rich Plasma, and Minoxidil for Androgenetic Alopecia Treatment. Cureus. 2025;17:e87875. DOI: 10.7759/cureus.87875. PMCID: PMC12351504.
Cosmo Pharmaceuticals. Phase III Topline Results SCALP 1 and SCALP 2 for Clascoterone 5% Solution in Male AGA. Press release. December 3, 2025. https://www.cosmopharma.com/news/
Hordinsky M, Harbort D. Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia. HCPLive. May 2026. https://www.hcplive.com/
Guo R-X, et al. Research progress in the treatment of non-scarring alopecia: mechanism and treatment. Front Pharmacol. 2025. DOI: 10.3389/fphar.2025.1544068. PMCID: PMC12141338.
Chen M, et al. Low-dose oral minoxidil does not significantly affect blood pressure: a systematic review and meta-analysis. J Am Acad Dermatol. 2025;92:554–555.
Frontiers in Pharmacology. Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia. Front Pharmacol. 2026. DOI: 10.3389/fphar.2026.1776134.
MDPI Cosmetics. Promises and Pitfalls of Regenerative Therapies for AGA: PRP, Photobiomodulation, Stem Cells, and Exosomes. Cosmetics. 2026;14(1):5. https://www.mdpi.com/2076-3271/14/1/5
MDPI Cosmetics. Regenerative Strategies for Androgenetic Alopecia: Evidence, Mechanisms, and Translational Pathways. Cosmetics. 2026;13(1):19. https://www.mdpi.com/2079-9284/13/1/19
Annals of Dermatology. Updates in Treatment for Androgenetic Alopecia. Ann Dermatol. 2025. DOI: 10.5021/ad.25.042. PMCID: PMC12715879.
DermNet NZ. Clascoterone. Last reviewed July 2025. https://dermnetnz.org/topics/clascoterone
SCIRP. The Pathogenesis and Treatment Progress of Androgenic Alopecia. June 2024. https://www.scirp.org/journal/paperinformation?paperid=133926
MDPI Cosmetics. Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia. Cosmetics. 2025;12(6):287. https://www.mdpi.com/2079-9284/12/6/287
2026-04-27
时隔十年，印度制药行业老大再度上演蛇吞象式并购豪赌。
4 月 27 日，太阳制药宣布以 117.5 亿美元收购美国欧加隆（Organon），这是印度药企历史上规模最大的跨境收购案。欧加隆 2021 年从默沙东分拆独立，主要聚焦女性健康、生物类似药和成熟品牌药三大业务板块，2025 年公司全年收入为 62 亿美元（-3%）。
此次收购是太阳制药转型高价值专科药、完善全球产业布局的关键落子，交易完成后，其收入有望突破 120 亿美元，跻身全球 TOP 25 药企行列。不过，欧加隆最终能否成为太阳制药新的增长引擎尚未可知，毕竟大型并购后消化不良的案例比比皆是。
自成立以来，太阳制药的发展始终伴随着大胆布局与战略豪赌。从仿制药到高端仿制药，从品牌药再到创新药，从一家仅有几名员工的小作坊到如今的医药巨擎，太阳制药的崛起是一部精准的资本运作史，更是一部极具耐心的战略扩张史。
起家：「冷门」赛道掘金
印度在独立初期，80%-90% 的药品都由跨国药企供应，这直接导致了国内药价居高不下，普通民众甚至连基础药品都负担不起。为了摆脱辖制，印度政府在 20 世纪 70 年代出台了一系列政策，包括废除产品专利、缩短工艺专利期限、限制外资持股比例、控制药品价格、强制本土生产等。制度的红利催生出了一大批本土药企，印度仿制药开始爆发。
太阳制药就诞生在这个时期。1983 年，年仅 28 岁的 Dilip Shanghv 在父亲的药品批发公司工作一段时间后，决定自己生产药品。他不想在原料药、抗生素、消炎药等主流赛道，与西普拉等巨头正面硬刚，于是另辟蹊径，打算生产壁垒更高的精神类药物，这也为太阳制药后来的高利润增长打下了基础。
当时的太阳制药还是个小作坊，只有 5 种精神科产品和一两人的营销团队。好在差异化竞争策略，让太阳制药在很短的时间内，就获得了医生和患者的认可，同时建立了专业的品牌形象。1987 年，太阳制药的精神类仿制药已经销往了印度全国各地。
不满足于此，在精神科市场站稳脚跟后，太阳制药又开始有计划地将这一模式复制到其他领域。1998 年，它推出了首批心脏病学产品 Monotrate（单硝酸异山梨酯）和 Angize（地尔硫䓬）。而后又将触角伸向了消化胃肠道领域，进一步扩大了公司在慢性疾病领域的市场份额。到 1990 年左右，太阳制药已经初具规模，盈利能力在同类公司中名列前茅。
发展：并购驱动增长
太阳制药真正的跃迁，来自于并购。它如同秃鹫般，吞食了不少重病缠身的公司，同时还通过技术输出、管理赋能、资源重组等方式，巧妙地把它们盘活，成为了公司发展的核心动力。
1994 年，太阳制药在印度证券交易所挂牌上市，获得了 55 倍的超额认购。这是 Dilip Shanghvi 从实业经营向资本运作跨越的关键转折，也为太阳制药后续的并购储备了充足的弹药。九十年代以来，太阳制药通过一系列极具战略远见的收购，迅速扩张了公司的全球版图。
来源：太阳制药报告
这些并购事件中，有一起称得上是史诗级的蛇吞象。2015 年 3 月，太阳制药以40 亿美元，从第一三共手中收购了印度另外一家巨头兰伯西（Ranbaxy）。这起并购，让太阳制药直接跃升成为了印度第一药企。
兰伯西成立于 1961 年，21 世纪初期就已经是美国首屈一指的仿制药巨头，风光无两。2008 年，急于进行全球化扩张的第一三共，以 46 亿美元将其收入囊中。可惜没多久，兰伯西就深陷合规危机，直接被美国市场封杀，业绩一落千丈。太阳制药正是在此刻对兰伯西出手的。
另外，从太阳制药的并购史，也可以清晰地看到它的发展路径，先是做大，实现产业链闭环，将成本控制到极限。然后是做强，将自身优势与海外资源相结合，完善全球化布局。
而近些年，随着仿制药利润空间压缩，太阳制药开始做新，交易目标也转向了创新药，包括引进默沙东的替拉珠单抗、灵北的伏硫西汀、Cassiopea 的克拉考特、诺华的卡马西平和索尼德吉，以及收购 Concert 获得氘代芦可替尼、收购 Checkpoint 获得柯希利单抗等等。
进阶：从仿制到创新
Dilip Shanghvi 在接受外媒采访时坦言：制药是典型的知识密集型行业，想要长久立足，就必须持续迭代自身能力，紧密跟踪全球行业趋势和成熟经验，并做出相应的战略调整。而扩展创新业务就是太阳制药现在以及未来要瞄定的方向。
其实十多年前，太阳制药就开始通过交易并购涉足创新领域了。近些年，太阳制药还一直在加大研发投入，2025 财年已经提高至 3.73 亿美元（324.84 亿卢比），其中特药研发支出 1.54 亿美元，与 2020 财年的 6500 万美元相比，显著增加。接下来，它还将进一步提高投资力度，以实现创新疗法领域的规模化发展。
来源：太阳制药年报
得益于源源不断的投入，太阳制药已经搭建起丰富的创新产品管线，其中进展到商业化阶段的就有 27 款。根据太阳制药财报，如今，创新业务收入已然成为其核心增长引擎之一，占总营收比例也逐年提高。
2025 财年，太阳制药创新药收入已经达到 12.16 亿美元，同比增长 17.1%，主要由 Ilumya（替拉珠单抗）、Winlevi（克拉考特）、Cequa（环孢菌素 A 滴眼液）和 Odomzo（索尼德吉）等核心产品驱动。2026 财年前三季度，其创新产品销售额更是突破了十亿美金，达到 10.67 亿美元，同比增长 15.7%。
来源：太阳制药投资者报告
除了已经上市的产品，太阳制药在研的新分子还有 Fibromun（L19TNF）、Nidlegy（L19IL2+L19TNF）、GL0034（GLP-1R 激动剂）、MM-II（化药）等等。其中 Nidlegy 已经推进至 III 期临床阶段，或许很快就能成为太阳制药新的业绩增量。
结语
太阳制药如今已经站在了新的发展起点上，开始全面向高端仿制药、专科药与创新药进阶。依托成熟的全球化运营经验与资本运作能力，太阳制药的创新转型值得期待。
封面来源：站酷海洛
免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。
编辑：月牙
PR 稿对接：微信 insightxb
投稿：微信 insightxb；邮箱 insight@dxy.cn
2026-04-14
太阳制药是印度最大的制药公司，也是全球仿制药行业最重要的玩家之一。
作为全球第四大仿制药企，太阳制药近些年在规模和增长上都保持着强劲势头。2024-2025 财年，太阳制药实现收入 60 亿美元（5204.12 亿卢比，2024.04-2025.03），同比增长 9%，2025-2026 财年前三季度营收已经达到 50.12 亿美元（2025.04-2025.12)，创下历史新高。
目前，太阳制药业务遍及 100 多个国家，在全球拥有 40 个生产基地和 4.3 万名员工，无论是产品规模还是全球布局，都已经跻身国际大药企行列。
从一家仅有几名员工的小作坊，成长为如今的医药巨擎，太阳制药用了整整 43 年。它是如何一步步崛起的？在仿制药竞争愈发激烈、利润空间不断压缩的今天，它又靠什么继续保持增长？太阳制药的发展路径，或许能给国内药企一些启发。
起家：「冷门」赛道掘金
印度在独立初期，80%-90% 的药品都由跨国药企供应，这直接导致了国内药价居高不下，普通民众甚至连基础药品都负担不起。为了摆脱辖制，印度政府在 20 世纪 70 年代出台了一系列政策，包括废除产品专利、缩短工艺专利期限、限制外资持股比例、控制药品价格、强制本土生产等。制度的红利催生出了一大批本土药企，印度仿制药开始爆发。
太阳制药就诞生在这个时期。1983 年，年仅 28 岁的 Dilip Shanghv 在父亲的药品批发公司工作一段时间后，决定自己生产药品。他不想在原料药、抗生素、消炎药等主流赛道，与西普拉等巨头正面硬刚，于是另辟蹊径，打算生产壁垒更高的精神类药物，这也为太阳制药后来的高利润增长打下了基础。
当时的太阳制药还是个小作坊，只有 5 种精神科产品和一两人的营销团队。好在差异化竞争策略，让太阳制药在很短的时间内，就获得了医生和患者的认可，同时建立了专业的品牌形象。1987 年，太阳制药的精神类仿制药已经销往了印度全国各地。
不满足于此，在精神科市场站稳脚跟后，太阳制药又开始有计划地将这一模式复制到其他领域。1998 年，它推出了首批心脏病学产品 Monotrate（单硝酸异山梨酯）和 Angize（地尔硫䓬）。而后又将触角伸向了消化胃肠道领域，进一步扩大了公司在慢性疾病领域的市场份额。到 1990 年左右，太阳制药已经初具规模，盈利能力在同类公司中名列前茅。
发展：并购驱动增长
太阳制药真正的跃迁，来自于并购。它如同秃鹫般，吞食了不少重病缠身的公司，同时还通过技术输出、管理赋能、资源重组等方式，巧妙地把它们盘活，成为了公司发展的核心动力。
1994 年，太阳制药在印度证券交易所挂牌上市，获得了 55 倍的超额认购。这是 Dilip Shanghvi 从实业经营向资本运作跨越的关键转折，也为太阳制药后续的并购储备了充足的弹药。九十年代以来，太阳制药通过一系列极具战略远见的收购，迅速扩张了公司的全球版图。
来源：太阳制药报告
这些并购事件中，有一起可以称得上是史诗级的蛇吞象。2015 年 3 月，太阳制药以40 亿美元，从第一三共手中收购了印度另外一家巨头兰伯西（Ranbaxy）。这起并购，让太阳制药直接跃升成为了印度第一药企。
兰伯西成立于 1961 年，21 世纪初期就已经是美国首屈一指的仿制药巨头，风光无两。2008 年，急于进行全球化扩张的第一三共，以 46 亿美元将其收入囊中。可惜没多久，兰伯西就深陷合规危机，直接被美国市场封杀，业绩一落千丈。太阳制药正是在此刻对兰伯西出手的。
另外，从太阳制药的并购史，也可以清晰地看到它的发展路径，先是做大，实现产业链闭环，将成本控制到极限。然后是做强，将自身优势与海外资源相结合，完善全球化布局。
而近些年，随着仿制药利润空间压缩，太阳制药开始做新，交易目标也转向了创新药，包括引进默沙东的替拉珠单抗、灵北的伏硫西汀、Cassiopea 的克拉考特、诺华的卡马西平和索尼德吉，以及收购 Concert 获得氘代芦可替尼、收购 Checkpoint 获得柯希利单抗等等。
进阶：从仿制到创新
Dilip Shanghvi 在接受外媒采访时坦言：制药是典型的知识密集型行业，想要长久立足，就必须持续迭代自身能力，紧密跟踪全球行业趋势和成熟经验，并做出相应的战略调整。而扩展创新业务就是太阳制药现在以及未来要瞄定的方向。
其实十多年前，太阳制药就开始通过交易并购涉足创新领域了。近些年，太阳制药还一直在加大研发投入，2025 财年已经提高至 3.73 亿美元（324.84 亿卢比），其中特药研发支出 1.54 亿美元，与 2020 财年的 6500 万美元相比，显著增加。接下来，它还将进一步提高投资力度，以实现创新疗法领域的规模化发展。
来源：太阳制药年报
得益于源源不断的投入，太阳制药已经搭建起丰富的创新产品管线，其中进展到商业化阶段的就有 27 款。根据太阳制药财报，如今，创新业务收入已然成为其核心增长引擎之一，占总营收比例也逐年提高。
2025 财年，太阳制药创新药收入已经达到 12.16 亿美元，同比增长 17.1%，主要由 Ilumya（替拉珠单抗）、Winlevi（克拉考特）、Cequa（环孢菌素 A 滴眼液）和 Odomzo（索尼德吉）等核心产品驱动。2026 财年前三季度，其创新产品销售额更是突破了十亿美金，达到 10.67 亿美元，同比增长 15.7%。
来源：太阳制药投资者报告
除了已经上市的产品，太阳制药在研的新分子还有 Fibromun（L19TNF）、Nidlegy（L19IL2+L19TNF）、GL0034（GLP-1R 激动剂）、MM-II（化药）等等。其中 Nidlegy 已经推进至 III 期临床阶段，或许很快就能成为太阳制药新的业绩增量。
结语
从仿制药到高端仿制药，再到专科药、创新药，太阳制药的崛起是一部精准的资本运作史，更是一部极具耐心的战略扩张史。
近日，太阳制药打算 120 亿美元收购欧加隆的消息，引发市场热议。如果成功，对于太阳制药而言，这或许又是个新的转折点。
封面来源：站酷海洛
免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。
编辑：月牙
PR 稿对接：微信 insightxb
投稿：微信 insightxb；邮箱 insight@dxy.cn
100 项与 Cassiopea SpA 相关的药物交易
登录后查看更多信息
100 项与 Cassiopea SpA 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2026年10月30日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
批准上市
1
1
其他
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用